Test immune-modulator treatments for rheumatoid arthritis with knee trouble
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old and able to consent to the study
- You have rheumatoid arthritis diagnosed using recognized ACR or ACR/EULAR criteria
- You have knee dysfunction (knee problems affecting daily function)
- If you’re in the osteoarthritis group: you meet 1995 knee osteoarthritis criteria and have knee dysfunction
- You do not have active hepatitis, active tuberculosis, or any ongoing infection or cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to find which of four biologic drugs works best for you if methotrexate didn't help or caused side effects. You'll get each drug in turn and track your symptoms to find your best match.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
Hear when a new Arthritis, Rheumatoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.